

A Brief Presented by
THE CANADIAN PHARMACEUTICAL ASSOCIATION, INC.
to the
HOUSE OF COMMONS' SPECIAL COMMITTEE ON DRUG COSTS AND
PRICES

We are pleased to present the Canadian Pharmaceutical Association before the House of Commons' Special Committee on Drug Costs and Prices. In so doing, it is our aim to make known the views of the Association and to factually disseminate its knowledge of matters having to do with drug costs in Canada, particularly with respect to their distribution and the provision of comprehensive pharmaceutical services by practising pharmacists in the widespread communities of Canada.

IDENTIFICATION AND ORIENTATION

1.1 The Canadian Pharmaceutical Association Inc. was founded in 1907 and incorporated by Federal Charter in 1924. It is representative of the Provincial Statutory Pharmacy Organizations in Canada and their over 8,000 registered pharmacists, excepting those of the Collège des Pharmaciens de la Province de Québec, which withdrew from constituent membership in the Association, effective July 1, 1962. Hence, the Association membership comprises pharmacists in all fields of pharmaceutical endeavour in Canada—community retail, hospital, teaching, industry, production control and distribution, government, armed forces, etc. In addition to the representatives of each Provincial Statutory Pharmacy Organization, there are seated on its Council the delegates of the Canadian Conference of Pharmaceutical Faculties, the Canadian Society of Hospital Pharmacists and the Canadian Society of Industrial Pharmacists. For the sake of clarity, we would point out that the latter bears no relation to the Pharmaceutical Manufacturers Association of Canada which is an organization of certain companies involved in the manufacture and distribution of pharmaceutical products in Canada.

Note: The initials "C.Ph.A." which appear from time to time in this Brief refer to the long-standing abbreviation of the name of the Canadian Pharmaceutical Association, Inc.

1.2 The views of Canadian Pharmacy respecting drug costs and prices and related matters having an effect, direct or indirect, on the health and welfare of Canadians have, from time to time, been made known by the Canadian Pharmaceutical Association in presentations both to legislators and to those charged with the administration of legislation. In particular, we respectfully draw the attention of the Special Committee on Drug Costs and Prices to the Briefs presented by the Association before hearings and meetings of (1) The Royal Commission on Government Organization, July 31, 1961; (2) The Restrictive Trade Practices Commission, October 24-27, 1961; (3) The Royal Commission on Health Services, May 25, 1962; (4) The Special Committee of the Royal College of Physicians and Surgeons reviewing new drugs, September 27, 1962; (5) The Royal Commission on Taxation, May 2, 1963; and (6) the